BPC-157, TB-500, and IGF-1 LR3 have no completed human trials at all
This is why most orthopedic guidelines now limit cortisone injections to 3-4 per joint per year
The information below is drawn from individual-compound research and community reports, separated into compound-level effects and stack-specific concerns
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
From UndisclosedComments about Cyanocobalamin Injection, 1000 mcg/mL 1mL Viallove the 1 ml vials
He's also said he hopes to relax restrictions around them but has been faced with some resistance within the FDA, which previously determined that some peptides lack sufficient safety data
